Abstract: The present disclosure relates to trial scleral lenses, and the resulting scleral lenses, designed for the asymmetric shape of the sclera and/or its chiral properties. In some embodiments, the scleral lenses are also designed for the specific asymmetry associated with different scleral diameters. In addition, as discussed herein, the scleral shape can vary with different conditions of the eye. By designing a set of trial scleral lenses that takes into account these different asymmetric properties of the sclera, a clinician can be more efficient, fitting more eyes with fewer subsequent modifications. The resulting lenses will also achieve a better fit.

Abstract: Methods and systems for manufacturing a wavefront-guided scleral lens prosthetic device customized for an eye of a patient include obtaining a first scleral lens prosthetic device with a central optic zone configured to vault over the eye's cornea and a peripheral haptic zone configured to align with the eye's sclera, collecting measurements of any offset and/or rotation of the first scleral lens prosthetic device relative to the eye's pupil and of any aberrations, particularly higher-order aberrations, generating a wavefront-guided profile from the measurements, and fabricating a second scleral lens prosthetic device with the profile on a surface of a central optic zone configured to vault over the eye's cornea and a peripheral haptic zone customized to align with the eye's sclera.

Abstract: The present disclosure relates to trial scleral lenses, and the resulting scleral lenses, designed for the asymmetric shape of the sclera and/or its chiral properties. In some embodiments, the scleral lenses are also designed for the specific asymmetry associated with different scleral diameters. In addition, as discussed herein, the scleral shape can vary with different conditions of the eye. By designing a set of trial scleral lenses that takes into account these different asymmetric properties of the sclera, a clinician can be more efficient, fitting more eyes with fewer subsequent modifications. The resulting lenses will also achieve a better fit.

Abstract: The present disclosure relates to trial scleral lenses, and the resulting scleral lenses, designed for the asymmetric shape of the sclera and/or its chiral properties. In some embodiments, the scleral lenses are also designed for the specific asymmetry associated with different scleral diameters. In addition, as discussed herein, the scleral shape can vary with different conditions of the eye. By designing a set of trial scleral lenses that takes into account these different asymmetric properties of the sclera, a clinician can be more efficient, fitting more eyes with fewer subsequent modifications. The resulting lenses will also achieve a better fit.

Abstract: A scleral lens is provided with a sodium channel blocker or a sodium channel modulator disposed in the pre-corneal tear film between the scleral lens and the cornea. This system can be used to deliver sodium channel blockers or a sodium channel modulators not currently used because of poor bioavailability. Methods of using this sodium channel blocker delivery system or a sodium channel modulator delivery system are also disclosed.

Abstract: The present disclosure relates to trial scleral lenses, and the resulting scleral lenses, designed for the asymmetric shape of the sclera and/or its chiral properties. In some embodiments, the scleral lenses are also designed for the specific asymmetry associated with different scleral diameters. In addition, as discussed herein, the scleral shape can vary with different conditions of the eye. By designing a set of trial scleral lenses that takes into account these different asymmetric properties of the sclera, a clinician can be more efficient, fitting more eyes with fewer subsequent modifications. The resulting lenses will also achieve a better fit.

Abstract: Methods and systems for manufacturing a wavefront-guided scleral lens prosthetic device customized for an eye of a patient include obtaining a first scleral lens prosthetic device with a central optic zone configured to vault over the eye's cornea and a peripheral haptic zone configured to align with the eye's sclera, collecting measurements of any offset and/or rotation of the first scleral lens prosthetic device relative to the eye's pupil and of any aberrations, particularly higher-order aberrations, generating a wavefront-guided profile from the measurements, and fabricating a second scleral lens prosthetic device with the profile on a surface of a central optic zone configured to vault over the eye's cornea and a peripheral haptic zone customized to align with the eye's sclera.

Abstract: A scleral lens is provided with a sodium channel blocker or a sodium channel modulator disposed in the pre-corneal tear film between the scleral lens and the cornea. This system can be used to deliver sodium channel blockers or a sodium channel modulators not currently used because of poor bioavailability. Methods of using this sodium channel blocker delivery system or a sodium channel modulator delivery system are also disclosed.

Abstract: A scleral lens is provided with a sodium channel blocker or a sodium channel modulator disposed in the pre-corneal tear film between the scleral lens and the cornea. This system can be used to deliver sodium channel blockers or a sodium channel modulators not currently used because of poor bioavailability. Methods of using this sodium channel blocker delivery system or a sodium channel modulator delivery system are also disclosed.

Abstract: A scleral lens is provided with a sodium channel blocker or a sodium channel modulator disposed in the pre-corneal tear film between the scleral lens and the cornea. This system can be used to deliver sodium channel blockers or a sodium channel modulators not currently used because of poor bioavailability. Methods of using this sodium channel blocker delivery system or a sodium channel modulator delivery system are also disclosed.

Abstract: Methods and systems for manufacturing a wavefront-guided scleral lens prosthetic device customized for an eye of a patient include obtaining a first scleral lens prosthetic device with a central optic zone configured to vault over the eye's cornea and a peripheral haptic zone configured to align with the eye's sclera, collecting measurements of any offset and/or rotation of the first scleral lens prosthetic device relative to the eye's pupil and of any aberrations, particularly higher-order aberrations, generating a wavefront-guided profile from the measurements, and fabricating a second scleral lens prosthetic device with the profile on a surface of a central optic zone configured to vault over the eye's cornea and a peripheral haptic zone customized to align with the eye's sclera.

Abstract: The present invention provides a scleral lens which includes channels on its posterior bearing surface that improve the flow of tears between the bearing surface of the device and the underlying scleral eyes tissue into the space between the optic of the lens and cornea. The channels are disposed on the inside surface of the lens and extend generally radially from the inside of the haptic and the outside rim of the lens. Various configurations are possible for the channels, as described in more detail below. Additionally, the channels can have a serpentine or arcuate configuration to allow for the appropriate amount of fluid flow between the space under the lens and the scleral surface of the eye. In another embodiment, microchannels can be formed in the lens to increase the oxygen permeability of the lens. The microchannels can have many configurations that reduce the volume of the lens material.

Abstract: A scleral lens is provided with a sodium channel blocker or a sodium channel modulator disposed in the pre-corneal tear film between the scleral lens and the cornea. This system can be used to deliver sodium channel blockers or a sodium channel modulators not currently used because of poor bioavailability. Methods of using this sodium channel blocker delivery system or a sodium channel modulator delivery system are also disclosed.

Abstract: A scleral lens is provided with a sodium channel blocker or a sodium channel modulator disposed in the pre-corneal tear film between the scleral lens and the cornea. This system can be used to deliver sodium channel blockers or a sodium channel modulators not currently used because of poor bioavailability. Methods of using this sodium channel blocker delivery system or a sodium channel modulator delivery system are also disclosed.

Abstract: The present invention provides a scleral lens which includes channels on its posterior bearing surface that improve the flow of tears between the bearing surface of the device and the underlying scleral eyes tissue into the space between the optic of the lens and cornea. The channels are disposed on the inside surface of the lens and extend generally radially from the inside of the haptic and the outside rim of the lens. Various configurations are possible for the channels, as described in more detail below. Additionally, the channels can have a serpentine or arcuate configuration to allow for the appropriate amount of fluid flow between the space under the lens and the scleral surface of the eye. In another embodiment, microchannels can be formed in the lens to increase the oxygen permeability of the lens. The microchannels can have many configurations that reduce the volume of the lens material.

Abstract: A scleral lens is provided with scalloped channels on its posterior surface to improve the flow of fluid between the scleral lens and the eye. Also provided is a scleral lens with a fenestrated channel circumscribing the intersection of the optic portion and the scleral portion of the lens. The circumferential fenestrated channel prevents adhesion and suction between the lens and the eye, and improves comfort, vision, and the fitting process.

Abstract: The present invention provides a scleral lens which includes channels on its posterior bearing surface that improve the flow of tears between the bearing surface of the device and the underlying scleral eyes tissue into the space between the optic of the lens and cornea. The channels are disposed on the inside surface of the lens and extend generally radially from the inside of the haptic and the outside rim of the lens. Various configurations are possible for the channels, as described in more detail below. Additionally, the channels can have a serpentine or arcuate configuration to allow for the appropriate amount of fluid flow between the space under the lens and the scleral surface of the eye. In another embodiment, microchannels can be formed in the lens to increase the oxygen permeability of the lens. The microchannels can have many configurations that reduce the volume of the lens material.

Abstract: A scleral lens is provided with a drug that is retained in the reservoir of fluid between the scleral lens and the cornea. This system can be used to deliver drugs not currently used because of poor bioavailability, to increase bioavailability of drugs used in patients already wearing a scleral lens, and to improve bioavailability in patients who are not currently wearing the lens. Dosing can be provided less frequently, thus decreasing the risk of non-compliance.

Abstract: A scleral lens is provided with a drug that is retained in the reservoir of fluid between the scleral lens and the cornea. This system can be used to deliver drugs not currently used because of poor bioavailability, to increase bioavailability of drugs used in patients already wearing a scleral lens, and to improve bioavailability in patients who are not currently wearing the lens. Dosing can be provided less frequently, thus decreasing the risk of non-compliance.

Abstract: A scleral lens is provided with a drug that is retained in the reservoir of fluid between the scleral lens and the cornea. This system can be used to deliver drugs not currently used because of poor bioavailability, to increase bioavailability of drugs used in patients already wearing a scleral lens, and to improve bioavailability in patients who are not currently wearing the lens. Dosing can be provided less frequently, thus decreasing the risk of non-compliance.